靶向共刺激受体途径增强肿瘤免疫治疗的研究进展  

Research progress of targeted costimulatory receptor pathway to enhance tumor immunotherapy

作　　者：王会剑 白宇[1] WANG Huijian;BAI Yu(Department of Urology,the Third Affiliated Hospital of Kunming Medical University,Yunnan Province,Kunming 650000,China)

机构地区：[1]昆明医科大学第三附属医院泌尿外科,云南昆明650000

出　　处：《中国医药导报》2023年第23期43-46,共4页China Medical Herald

基　　金：国家自然科学基金资助项目(82160511)。

摘　　要：不同类型免疫检查点抑制剂(ICIS)的发现和临床应用彻底改变了肿瘤的治疗方法。这一方法改善了各种类型晚期肿瘤患者的预后;然而现有抗细胞毒性T淋巴细胞相关蛋白4、程序性死亡受体1和程序性死亡配体1在不同类型肿瘤患者中疗效差异较大,因此越来越多的研究致力于探索出更多的ICIS。本文讨论了针对共刺激T细胞受体药物的转化潜力和临床发展,并概述了正在进行的新型ICIS的临床试验,包括共刺激受体相关蛋白和诱导T细胞共刺激受体的激动剂。需要进一步努力的方向是如何优化联合ICIS治疗的时机并且根据患者特异性和肿瘤特异性进行个体化免疫治疗,以及不断推进免疫监测技术的发展。The discovery and clinical application of different types of immune checkpoint inhibitors(ICIS)have revolutionized the treatment of cancer.This approach improved the prognosis of patients with various types of advanced tumors;however,the efficacy of anti-cytotoxic T lymphocyt-associated protein 4,programmed death receptor 1,and programmed death ligand 1 in patients with different tumor types varies greatly.Therefore,more and more studies are devoted to exploring more ICIS.This article discusses the transformation potential and clinical development of drugs targeting costimulatory T cell receptors,and outlines ongoing clinical trials of novel ICIS,including costimulatory receptor associated proteins and agonists that induce T cell costimulatory receptors.Further efforts are needed to optimize the timing of combined ICIS therapy and to tailor immunotherapy to patient and tumor specificity,as well as to advance the development of immunosurveillance techniques.

关 键 词：免疫检查点抑制剂 共刺激受体 肿瘤微环境 免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]